CoPP Nrf2 MAREs cobalt protoporrphyrin NF-E2 related factor Maf recognition elements References 1 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non- alcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306–317. 2 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99–S112. 3 Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842–845. 4 Nan YM, Wu WJ, Fu N, and et al. Antioxidants vitamin E and 1-amino- benzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009; 15: 1–11. 5 Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 2009; 47: 924– 931. 6 Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr 2008; 138: 1872–1879. 7 Hirose A, Ono M, Saibara T, and et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375–1381. 8 Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma trans- forming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667–1672. 9 Dufour JF, Oneta CM, Gonvers JJ, and et al. Swiss Association for the Study of the Liver: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537–1543. 10 Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steato- hepatitis. Am J Gastroenterol 2003; 98: 2485–2490. 11 Nakamoto K, Takayama F, Mankura M, and et al. Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. J Clin Biochem Nutr 2009; 44: 239–246. 12 Takahashi T, Shimizu H, Morimatsu H, and et al. Heme oxygenase-1 is an essential cytoprotective component in oxidative tissue injury induced by hemorrhagic shock. J Clin Biochem Nutr 2009; 44: 28–40. 13 Hayashi S, Omata Y, Sakamoto H, and et al. Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 2004; 336: 241–250. 14 Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005; 42: 585–591. 15 Liu LG, Yan H, Zhang W, and et al. Induction of heme oxygenase-1 in human hepatocytes to protect them from ethanol-induced cytotoxicity. Biomed Environ Sci 2004; 17: 315–326. 16 Yao P, Li K, Song F, and et al. Heme oxygenase-1 upregulated by Ginkgo biloba extract: potential protection against ethanol-induced oxidative liver damage. Food Chem Toxicol 2007; 45: 1333–1342. 17 McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ. Curcumin induces heme oxygenase-1 in hepatocytes and is protective in simulated cold preservation and warm reperfusion injury. Transplantation 2006; 81: 623– HE ZnPP αSMA hematoxylin and eosin zinc protoporphyrin alpha smooth muscle actin 626. 18 Sun J, Hoshino H, Takaku K, and et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002; 21: 5216– 5224. 19 Iida A, Inagaki K, Miyazaki A, Yonemori F, Ito E, Igarashi K. Bach1 deficiency ameliorates hepatic injury in a mouse model. Tohoku J Exp Med 2009; 217: 223–229. 20 Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911–917. 21 Yano Y, Ozono R, Oishi Y, and et al. Genetic ablation of the transcription repressor Bach1 leads to myocardial protection against ischemia/reperfusion in mice. Genes Cells 2006; 11: 791–803. 22 Yoshida T, Kikuchi G. Reaction of the microsomal heme oxygenase with cobaltic protoporphyrin IX, and extremely poor substrate. J Biol Chem 1978; 253: 8479–8482. 23 Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 2009; 50: 1226–1235. 24 Hintze KJ, Katoh Y, Igarashi K, Theil EC. Bach1 repression of ferritin and thioredoxin reductase1 is heme-sensitive in cells and in vitro and coordinates expression with heme oxygenase1, beta-globin, and NADP(H) quinone (oxido) reductase1. J Biol Chem 2007; 282: 34365–34371. 25 Farombi EO, Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol 2006; 39: 479–491. 26 Wang F, Duan ZJ, Sun YJ. Influence of heme oxygenase-1 expression on immune liver fibrosis induced by cobalt protoporphyrin in rats. World J Gastroenterol 2009; 15: 3009–3014. 27 Schmidt R, Tritschler E, Hoetzel A, and et al. Heme oxygenase-1 induction by the clinically used anesthetic isoflurane protects rat livers from ischemia/ reperfusion injury. Ann Surg 2007; 245: 931–942. 28 de Lima VM, de Oliveira CP, Sawada LY, and et al. Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient diet. Liver Int 2007; 27: 227–234. 29 Stefano JT, de Oliveira CP, Corrêa-Giannella ML, and et al. Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and micro- somal triglyceride transfer protein (MTP). Dig Dis Sci 2007; 52: 3448–3454. 30 Mantena SK, Vaughn DP, Andringa KK, and et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183–193. 31 Hensley K, Kotake Y, Sang H, and et al. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mito- chondria. Carcinogenesis 2000; 21: 983–989. 32 Li L, Grenard P, Nhieu JT, and et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003; 125: 460– 469. 33 Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet- induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 2004; 81: 243–248. 34 Takayama F, Egashira T, Kawasaki H, and et al. A novel animal model of nonalcoholic steatohepatitis (NASH): hypoxemia enhances the development of NASH. J Clin Biochem Nutr 2009; 45: 335–340. 166 doi: 10.3164/jcbn.09122GFR ©2011 JCBN